| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 210.13K | 224.1K | 329.33K | 429.8K | 283.27K | 239.23K | 190.94K | 65.41K | 0 | 43.47M |
| Revenue Growth % | 0.11% | 0.07% | 0.47% | 0.31% | -0.34% | -0.16% | -0.2% | -0.66% | -1% | - |
| Cost of Goods Sold | 318.72K | 366.67K | 114.96K | 396.79K | 373.23K | 204.85K | 148.94K | 3.73K | 205.56K | 3.19M |
| COGS % of Revenue | 1.52% | 1.64% | 0.35% | 0.92% | 1.32% | 0.86% | 0.78% | 0.06% | - | 0.07% |
| Gross Profit | -108.59K | -142.57K | 214.36K | 33.01K | -89.97K | 34.38K | 42K | 61.67K | -205.56K | 40.28M |
| Gross Margin % | -0.52% | -0.64% | 0.65% | 0.08% | -0.32% | 0.14% | 0.22% | 0.94% | - | 0.93% |
| Gross Profit Growth % | 0.58% | -0.31% | 2.5% | -0.85% | -3.73% | 1.38% | 0.22% | 0.47% | -4.33% | 196.96% |
| Operating Expenses | 16.55M | 24.62M | 33.14M | 26.9M | 20.92M | 27.26M | 29.48M | 30.69M | 48.75M | 62.64M |
| OpEx % of Revenue | 78.74% | 109.85% | 100.62% | 62.58% | 73.85% | 113.93% | 154.4% | 469.14% | - | 1.44% |
| Selling, General & Admin | 10.26M | 8.88M | 8.65M | 8.07M | 0 | 13.88M | 16.35M | 20.01M | 35.6M | 58.7M |
| SG&A % of Revenue | 48.84% | 39.64% | 26.27% | 18.79% | - | 58.01% | 85.61% | 305.87% | - | 1.35% |
| Research & Development | 6.28M | 15.74M | 24.49M | 18.82M | 11.05M | 13.38M | 13.13M | 10.68M | 13.16M | 3.94M |
| R&D % of Revenue | 29.89% | 70.21% | 74.35% | 43.79% | 39.02% | 55.92% | 68.78% | 163.28% | - | 0.09% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 9.87M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.65M | -24.76M | -32.92M | -26.86M | -21.01M | -27.22M | -29.44M | -30.62M | -48.96M | -22.36M |
| Operating Margin % | -79.26% | -110.49% | -99.97% | -62.5% | -74.16% | -113.78% | -154.18% | -468.2% | - | -0.51% |
| Operating Income Growth % | -0.87% | -0.49% | -0.33% | 0.18% | 0.22% | -0.3% | -0.08% | -0.04% | -0.6% | 0.54% |
| EBITDA | -16.64M | -24.74M | -32.89M | -26.79M | -20.93M | -27.08M | -29.26M | -30.41M | -48.89M | -22.05M |
| EBITDA Margin % | -79.18% | -110.37% | -99.86% | -62.33% | -73.9% | -113.18% | -153.25% | -465% | - | -0.51% |
| EBITDA Growth % | -0.87% | -0.49% | -0.33% | 0.19% | 0.22% | -0.29% | -0.08% | -0.04% | -0.61% | 0.55% |
| D&A (Non-Cash Add-back) | 15.08K | 25.6K | 36.89K | 74.22K | 73.29K | 143.49K | 177.02K | 209.04K | 70.75K | 309.78K |
| EBIT | -18.18M | -24.64M | -33M | -26.83M | -21.01M | -27.16M | -29.44M | -30.26M | -46.3M | -19.29M |
| Net Interest Income | 56.43K | 125.46K | 105.09K | 34.74K | -464.82K | 82.84K | -1.54K | 299.5K | 2.68M | 2.54M |
| Interest Income | 60.39K | 126.77K | 110.71K | 36.62K | 322.67K | 116.06K | 14.4K | 326.02K | 2.68M | 2.58M |
| Interest Expense | 3.96K | 1.31K | 5.62K | 1.87K | 787.49K | 33.23K | 15.94K | 26.52K | 0 | 36.41K |
| Other Income/Expense | -1.53M | 117.29K | -85.8K | 34.57K | 9.64M | 23.67K | -22.83K | 336.65K | 2.62M | 3.03M |
| Pretax Income | -18.19M | -24.64M | -33.01M | -26.83M | -11.37M | -27.2M | -29.46M | -30.29M | -46.34M | -19.32M |
| Pretax Margin % | -86.55% | -109.96% | -100.23% | -62.42% | -40.15% | -113.69% | -154.29% | -463.05% | - | -0.44% |
| Income Tax | 3.96K | 1.31K | -31.27K | 36.44K | 5.06M | -5.17M | -1.25M | -585.62K | 0 | -1.39M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1.45% | 0.81% | 0.96% | 0.98% | 1% | 0.93% |
| Net Income | -18.19M | -24.64M | -33.01M | -26.83M | -16.43M | -22.03M | -28.21M | -29.7M | -46.34M | -17.93M |
| Net Margin % | -86.55% | -109.96% | -100.23% | -62.42% | -58.01% | -92.08% | -147.75% | -454.1% | - | -0.41% |
| Net Income Growth % | 0.11% | -0.35% | -0.34% | 0.19% | 0.39% | -0.34% | -0.28% | -0.05% | -0.56% | 0.61% |
| Net Income (Continuing) | -18.19M | -24.64M | -33.01M | -26.83M | -16.43M | -22.03M | -28.21M | -29.7M | -46.34M | -17.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.90 | -3.25 | -2.99 | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 |
| EPS Growth % | 0.39% | -0.12% | 0.08% | 0.49% | 0.55% | -0.13% | 0.03% | 0.01% | -0.23% | 0.67% |
| EPS (Basic) | -2.90 | -3.25 | -2.99 | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 |
| Diluted Shares Outstanding | 6.27M | 7.59M | 11.03M | 17.82M | 24.15M | 28.56M | 37.67M | 40.27M | 50.9M | 58.87M |
| Basic Shares Outstanding | 6.27M | 7.59M | 11.03M | 17.82M | 24.15M | 28.56M | 37.61M | 40.14M | 50.9M | 58.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 37.06M | 21.83M | 13.27M | 18.67M | 29.35M | 48.18M | 66.47M | 59.55M | 79.45M | 114.58M |
| Cash & Short-Term Investments | 35.39M | 20.17M | 11.98M | 17.62M | 28.51M | 46.35M | 65.47M | 59.02M | 76.03M | 51.69M |
| Cash Only | 11.82M | 8.06M | 10.38M | 17.62M | 16.53M | 41.91M | 53.32M | 43.37M | 43.64M | 40.65M |
| Short-Term Investments | 23.57M | 12.1M | 1.6M | 0 | 11.98M | 4.44M | 12.15M | 15.64M | 32.39M | 11.04M |
| Accounts Receivable | 315.77K | 12.01K | 64.15K | 10.9K | 0 | 3.36K | 45.37K | 0 | 0 | 51.65M |
| Days Sales Outstanding | 548.5 | 19.57 | 71.1 | 9.26 | - | 5.12 | 86.73 | - | - | 433.69 |
| Inventory | 376.57K | 166.73K | 594.19K | 428.51K | 338.46K | 143.56K | 3.01K | 0 | 2.11M | 7.6M |
| Days Inventory Outstanding | 431.25 | 165.97 | 1.89K | 394.19 | 331 | 255.81 | 7.37 | - | 3.74K | 869.39 |
| Other Current Assets | 601.72K | 1.12M | 258.2K | 179.67K | 54.83K | 273.52K | 902.05K | -91.3K | 959.67K | 3.48M |
| Total Non-Current Assets | 42.87K | 74.69K | 186.28K | 160.86K | 126.82K | 1.13M | 2.48M | 2.49M | 2.61M | 4.27M |
| Property, Plant & Equipment | 37.87K | 69.69K | 186.28K | 160.86K | 126.82K | 1.13M | 2.37M | 2.38M | 2.51M | 2.32M |
| Fixed Asset Turnover | 5.55x | 3.22x | 1.77x | 2.67x | 2.23x | 0.21x | 0.08x | 0.03x | - | 18.73x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.84M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5K | 5K | 0 | 0 | 0 | 0 | 102.31K | 102.32K | 103.06K | 105.37K |
| Total Assets | 37.1M | 21.91M | 13.45M | 18.83M | 29.48M | 49.31M | 68.95M | 62.04M | 82.06M | 118.85M |
| Asset Turnover | 0.01x | 0.01x | 0.02x | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x | - | 0.37x |
| Asset Growth % | 6.28% | -0.41% | -0.39% | 0.4% | 0.57% | 0.67% | 0.4% | -0.1% | 0.32% | 0.45% |
| Total Current Liabilities | 3.06M | 4.09M | 6.26M | 7.77M | 5.83M | 4.16M | 5.35M | 6.31M | 11.4M | 33.84M |
| Accounts Payable | 1.71M | 1.65M | 1.81M | 2.59M | 1.02M | 1.13M | 2.21M | 2.2M | 4.28M | 1.72M |
| Days Payables Outstanding | 1.96K | 1.64K | 5.74K | 2.38K | 1K | 2.01K | 5.41K | 215.26K | 7.6K | 196.79 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 130.41K | 104.21K | 88.4K | 11.03K | 2.21K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 3.61M | 4.06M | 3.51M | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 12.11x | 5.34x | 2.12x | 2.40x | 5.04x | 11.58x | 12.44x | 9.44x | 6.97x | 3.39x |
| Quick Ratio | 11.98x | 5.29x | 2.02x | 2.35x | 4.98x | 11.54x | 12.43x | 9.44x | 6.78x | 3.16x |
| Cash Conversion Cycle | -977.87 | -1.45K | -3.78K | -1.98K | - | -1.75K | -5.32K | - | - | 1.11K |
| Total Non-Current Liabilities | 28.88K | 0 | 0 | 6.13M | 2.68K | 923.71K | 802.43K | 667.63K | 517.01K | 349.09K |
| Long-Term Debt | 0 | 0 | 0 | 6.13M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.68K | 923.71K | 802.43K | 667.63K | 517.01K | 349.09K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.09M | 4.09M | 6.26M | 13.89M | 5.83M | 5.09M | 6.15M | 6.98M | 11.92M | 34.19M |
| Total Debt | 0 | 0 | 0 | 6.13M | 4.69K | 1.03M | 923.8K | 802.43K | 667.63K | 517.01K |
| Net Debt | -11.82M | -8.06M | -10.38M | -11.5M | -16.52M | -40.87M | -52.39M | -42.57M | -42.98M | -40.13M |
| Debt / Equity | - | - | - | - | - | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -4201.30x | -18887.05x | -5859.43x | -14342.87x | -26.68x | -819.26x | -1846.43x | -1154.97x | - | -614.10x |
| Total Equity | 34.01M | 17.81M | -152.17M | -178.99M | -195.42M | 44.22M | 62.8M | 55.06M | 70.14M | 84.66M |
| Equity Growth % | 8.36% | -0.48% | -9.54% | -0.18% | -0.09% | 1.23% | 0.42% | -0.12% | 0.27% | 0.21% |
| Book Value per Share | 5.43 | 2.35 | -13.80 | -10.05 | -8.09 | 1.55 | 1.67 | 1.37 | 1.38 | 1.44 |
| Total Shareholders' Equity | 34.01M | 17.81M | -152.17M | -178.99M | -195.42M | 44.22M | 62.8M | 55.06M | 70.14M | 84.66M |
| Common Stock | 35.96K | 40.43K | 71.41K | 108.88K | 25.66K | 33.56K | 38.09K | 42.81K | 54.94K | 64.41K |
| Retained Earnings | -94.39M | -119.16M | -152.17M | -178.99M | -195.42M | -217.45M | -245.66M | -275.36M | -321.7M | -339.63M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 62.13K | 81.19K | 98.43K | 96.52K | 97.26K | 102K | 87.13K | 82.74K | 94.11K | 90.65K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.53M | -22.27M | -28.59M | -23.7M | -15.05M | -21.97M | -21.16M | -24.36M | -38.41M | -50.61M |
| Operating CF Margin % | -59.61% | -99.35% | -86.8% | -55.14% | -53.14% | -91.83% | -110.8% | -372.38% | - | -1.16% |
| Operating CF Growth % | -0.98% | -0.78% | -0.28% | 0.17% | 0.36% | -0.46% | 0.04% | -0.15% | -0.58% | -0.32% |
| Net Income | -18.19M | -24.64M | -33.01M | -26.83M | -16.43M | -22.03M | -28.21M | -29.7M | -46.34M | -17.93M |
| Depreciation & Amortization | 15.08K | 25.6K | 36.89K | 74.22K | 73.29K | 127.96K | 61.89K | 84.62K | 70.75K | 309.78K |
| Stock-Based Compensation | 3.23M | 1.34M | 1.66M | 1.11M | 2.44M | 2.5M | 5.04M | 4.07M | 5.49M | 6.13M |
| Deferred Taxes | 0 | 0 | -4.57M | -3.13M | -578.95K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.82M | 130K | 4.42M | 3.13M | 1.38M | 78.37K | 115.13K | 124.42K | 134.81K | 284.58K |
| Working Capital Changes | 598.66K | 887.48K | 2.88M | 1.94M | -1.93M | -2.65M | 1.84M | 1.07M | 2.23M | -39.41M |
| Change in Receivables | -248.19K | 307.77K | -47.6K | 51.99K | 10.63K | -3.09K | -44.08K | 42.14K | 0 | -51.79M |
| Change in Inventory | -38.54K | 79.84K | -100.46K | 165.68K | 59.28K | 149.6K | 145.46K | 3.01K | -2.11M | -5.49M |
| Change in Payables | 825.11K | -63.59K | 157.53K | 782.06K | -1.56M | 103.33K | 1.08M | -6.57K | 2.08M | -2.56M |
| Cash from Investing | -23.61M | 11.42M | 10.36M | 1.56M | -12.02M | 7.43M | -9.13M | -3.71M | -17.06M | 21.23M |
| Capital Expenditures | -15.45K | -58.72K | -151.99K | -48.89K | -36.57K | -112.64K | -1.43M | -219.36K | -327.3K | -115.73K |
| CapEx % of Revenue | 0.07% | 0.26% | 0.46% | 0.11% | 0.13% | 0.47% | 7.46% | 3.35% | - | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -23.59M | 11.48M | 10.51M | 1.6M | -11.98M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 43.63M | 7.09M | 20.52M | 29.4M | 25.8M | 40.1M | 41.76M | 17.9M | 55.92M | 26.32M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 15.18M | 863.1K | 6.8K | -70.94K | 10.57M | 411.75K | 301.92K | 128.63K | 89.3K | 7.44M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -12.54M | -22.32M | -28.74M | -23.75M | -15.09M | -22.08M | -22.58M | -24.58M | -38.74M | -50.73M |
| FCF Margin % | -59.69% | -99.61% | -87.27% | -55.26% | -53.27% | -92.3% | -118.26% | -375.74% | - | -1.17% |
| FCF Growth % | -0.98% | -0.78% | -0.29% | 0.17% | 0.36% | -0.46% | -0.02% | -0.09% | -0.58% | -0.31% |
| FCF per Share | -2.00 | -2.94 | -2.61 | -1.33 | -0.62 | -0.77 | -0.60 | -0.61 | -0.76 | -0.86 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.90x | 0.87x | 0.88x | 0.92x | 1.00x | 0.75x | 0.82x | 0.83x | 2.82x |
| Interest Paid | 3.96K | 1.2K | 5.62K | 1.87K | 12.55K | 33.23K | 15.94K | 26.52K | 34.3K | 36.41K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -96.62% | -95.1% | - | - | - | -49.81% | -52.72% | -50.4% | -74.02% | -23.17% |
| Return on Invested Capital (ROIC) | -116.25% | -116.27% | - | - | - | -609.35% | -321.02% | -200.66% | -185.19% | -46.78% |
| Gross Margin | -51.68% | -63.62% | 65.09% | 7.68% | -31.76% | 14.37% | 22% | 94.29% | - | 92.66% |
| Net Margin | -8655.37% | -10996.46% | -10023.45% | -6242.4% | -5801.29% | -9207.7% | -14774.7% | -45409.9% | - | -41.24% |
| Debt / Equity | - | - | - | - | - | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | -4201.30x | -18887.05x | -5859.43x | -14342.87x | -26.68x | -819.26x | -1846.43x | -1154.97x | - | -614.10x |
| FCF Conversion | 0.69x | 0.90x | 0.87x | 0.88x | 0.92x | 1.00x | 0.75x | 0.82x | 0.83x | 2.82x |
| Revenue Growth | 11.02% | 6.65% | 46.95% | 30.51% | -34.09% | -15.55% | -20.19% | -65.74% | -100% | - |
| 2020 | 2021 | |
|---|---|---|
| Europe | 237.03K | 190.94K |
| Europe Growth | - | -19.44% |
CorMedix Inc. (CRMD) reported $214.3M in revenue for fiscal year 2024.
CorMedix Inc. (CRMD) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, CorMedix Inc. (CRMD) is profitable, generating $162.5M in net income for fiscal year 2024 (-41.2% net margin).
CorMedix Inc. (CRMD) has a return on equity (ROE) of -23.2%. Negative ROE indicates the company is unprofitable.
CorMedix Inc. (CRMD) generated $74.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.